INTRODUCTION: Many clinicopathological studies do not specify the presence of other pathologies located within the brain, so disease heterogeneity may be under appreciated. OBJECTIVE: The purpose of this study was to determine the frequencies of concomitant pathologies among parkinsonian disorders. METHODS: Data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), an ongoing longitudinal clinical-neuropathological study, was used to analyze concomitant pathologies, including Alzheimer's disease (AD), argyrophilic grains (Arg), cerebral amyloid angiopathy (CAA), cerebral white matter rarefaction (CWMR) and overlap of each parkinsonian disorder in clinico-pathologically defined Parkinson's disease (PD; N = 140), dementia with Lewy bodies (DLB; N = 90), progressive supranuclear palsy (PSP; N = 64), multiple system atrophy (MSA; N = 6), corticobasal degeneration (CBD; N = 7); and normal elderly (controls; N = 166). RESULTS: Of the neuropathologically-confirmed PD cases, 38% had a concomitant diagnosis of AD, 9% PSP, 25% Arg, 44% CWMR, and 24% CAA. For DLB, 89% had AD, 1% PSP, 21% Arg, 51% CWMR, and 50% CAA. For PSP cases, 36% had AD, 20% PD, 1% DLB, 44% Arg, 52% CWMR and 25% CAA. Similar heterogeneity was seen for MSA and CBD cases. Many cases had more than one of the above additional diagnoses. CONCLUSIONS: These data demonstrate a great deal of concomitant pathologies among different types of parkinsonian disorders; this may help explain the heterogeneity of clinical findings.
INTRODUCTION: Many clinicopathological studies do not specify the presence of other pathologies located within the brain, so disease heterogeneity may be under appreciated. OBJECTIVE: The purpose of this study was to determine the frequencies of concomitant pathologies among parkinsonian disorders. METHODS: Data from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), an ongoing longitudinal clinical-neuropathological study, was used to analyze concomitant pathologies, including Alzheimer's disease (AD), argyrophilic grains (Arg), cerebral amyloid angiopathy (CAA), cerebral white matter rarefaction (CWMR) and overlap of each parkinsonian disorder in clinico-pathologically defined Parkinson's disease (PD; N = 140), dementia with Lewy bodies (DLB; N = 90), progressive supranuclear palsy (PSP; N = 64), multiple system atrophy (MSA; N = 6), corticobasal degeneration (CBD; N = 7); and normal elderly (controls; N = 166). RESULTS: Of the neuropathologically-confirmed PD cases, 38% had a concomitant diagnosis of AD, 9% PSP, 25% Arg, 44% CWMR, and 24% CAA. For DLB, 89% had AD, 1% PSP, 21% Arg, 51% CWMR, and 50% CAA. For PSP cases, 36% had AD, 20% PD, 1% DLB, 44% Arg, 52% CWMR and 25% CAA. Similar heterogeneity was seen for MSA and CBD cases. Many cases had more than one of the above additional diagnoses. CONCLUSIONS: These data demonstrate a great deal of concomitant pathologies among different types of parkinsonian disorders; this may help explain the heterogeneity of clinical findings.
Authors: Brittany N Dugger; Christopher M Clark; Geidy Serrano; Monica Mariner; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Ming Lu; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Simone P Zehntner; Alan P Carpenter; Abhinay D Joshi; Mark A Mintun; Michael J Pontecorvo; Daniel M Skovronsky; Lucia I Sue; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2014-01 Impact factor: 3.685
Authors: I Litvan; Y Agid; C Goetz; J Jankovic; G K Wenning; J P Brandel; E C Lai; M Verny; K Ray-Chaudhuri; A McKee; K Jellinger; R K Pearce; J J Bartko Journal: Neurology Date: 1997-01 Impact factor: 9.910
Authors: G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman Journal: Neurology Date: 1993-02 Impact factor: 9.910
Authors: Brittany N Dugger; Michael Malek-Ahmadi; Sarah E Monsell; Walter A Kukull; Bryan K Woodruff; Eric M Reiman; Thomas G Beach; Jeffrey Wilson Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs Journal: Mov Disord Date: 2019-02-06 Impact factor: 10.338
Authors: Gabor G Kovacs; Linda K Kwong; Murray Grossman; David J Irwin; Edward B Lee; John L Robinson; Eunran Suh; Vivianna M Van Deerlin; Virginia M Lee; John Q Trojanowski Journal: Brain Pathol Date: 2017-01-19 Impact factor: 6.508
Authors: Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger Journal: Lancet Neurol Date: 2017-06-13 Impact factor: 44.182
Authors: Gabor G Kovacs; John L Robinson; Sharon X Xie; Edward B Lee; Murray Grossman; David A Wolk; David J Irwin; Dan Weintraub; Christopher F Kim; Theresa Schuck; Ahmed Yousef; Stephanie T Wagner; Eunran Suh; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski Journal: J Neuropathol Exp Neurol Date: 2017-04-01 Impact factor: 3.685
Authors: Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Ann Neurol Date: 2020-09-12 Impact factor: 10.422
Authors: Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra Journal: J Alzheimers Dis Date: 2016-08-18 Impact factor: 4.472